Cargando…

Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study

Azilsartan is a novel angiotensin receptor blocker being developed for hypertension treatment. This 16-week, multicenter, randomized, double-blind study compared the efficacy and safety of azilsartan (20–40 mg once daily by forced titration) and its ability to provide 24-h blood pressure (BP) contro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rakugi, Hiromi, Enya, Kazuaki, Sugiura, Kenkichi, Ikeda, Yoshinori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348575/ https://www.ncbi.nlm.nih.gov/pubmed/22278628 http://dx.doi.org/10.1038/hr.2012.8

Ejemplares similares

Effect of azilsartan versus candesartan on morning blood pressure surges in Japanese patients with essential hypertension
por: Rakugi, Hiromi, et al.
Publicado: (2014)

Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study
por: Ito, Shuichi, et al.
Publicado: (2021)

Candesartan cilexetil in the treatment of chronic heart failure
por: Baguet, Jean-Philippe, et al.
Publicado: (2009)

Correction to: Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study
por: Ito, Shuichi, et al.
Publicado: (2022)

Candesartan cilexetil: COVID-19 pneumonia: case report
Publicado: (2020)

Repurposing Candesartan Cilexetil as Antibacterial Agent for MRSA Infection
por: Xu, Lanlan, et al.
Publicado: (2021)

Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T)
por: Bönner, Gerd, et al.
Publicado: (2011)

Design and development and evaluation of candesartan cilexetil liquid filling formulations
por: Deepthi, Y., et al.
Publicado: (2015)

Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex
por: Sravya, Maddukuri, et al.
Publicado: (2013)

Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials
por: Féghali, Ramzi EL, et al.
Publicado: (2007)

Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study
por: Baguet, JP, et al.
Publicado: (2009)

The Effect of Polysorbate 20 on Solubility and Stability of Candesartan Cilexetil in Dissolution Media
por: Hoppe, Katarzyna, et al.
Publicado: (2014)

Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug
por: Aly, Usama Farghaly, et al.
Publicado: (2020)

Formulation and Bioavailability of Novel Mucoadhesive Buccal Films for Candesartan Cilexetil in Rats
por: Mady, Omar Y., et al.
Publicado: (2021)

Chemometric Methods for Simultaneous Determination of Candesartan Cilexetil and Hydrochlorothiazide in Binary Combinations
por: Ali, Diyar Salahuddin
Publicado: (2023)

Enhanced Antihypertensive Activity of Candesartan Cilexetil Nanosuspension: Formulation, Characterization and Pharmacodynamic Study
por: Detroja, Chetan, et al.
Publicado: (2011)

Candesartan Cilexetil In Vitro–In Vivo Correlation: Predictive Dissolution as a Development Tool
por: Figueroa-Campos, Andrés, et al.
Publicado: (2020)

Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility
por: Mengden, Thomas, et al.
Publicado: (2009)

Development and characterization of controlled release polar lipid microparticles of candesartan cilexetil by solid dispersion
por: Kamalakkannan, V, et al.
Publicado: (2013)

Bioequivalence study of two formulations of candesartan cilexetil tablet in healthy subjects under fasting conditions
por: Tjandrawinata, Raymond R, et al.
Publicado: (2013)

Nephroprotective effects of Candesartan Cilexetil against Cyclosporine A-induced nephrotoxicity in a rat model
por: Ghafil, Fadhaa Abdulameer, et al.
Publicado: (2022)

The Anti-inflammatory Compound Candesartan Cilexetil Improves Neurological Outcomes in a Mouse Model of Neonatal Hypoxia
por: Quinlan, Sean, et al.
Publicado: (2019)

New simple spectrophotometric method for determination of the binary mixtures (atorvastatin calcium and ezetimibe; candesartan cilexetil and hydrochlorothiazide) in tablets
por: Belal, Tarek S., et al.
Publicado: (2013)

New Peceol™/Span™ 60 Niosomes Coated with Chitosan for Candesartan Cilexetil: Perspective Increase in Absolute Bioavailability in Rats
por: AbuElfadl, Aya, et al.
Publicado: (2021)

Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study
por: Rakugi, Hiromi, et al.
Publicado: (2022)

Developing pH-Modulated Spray Dried Amorphous Solid Dispersion of Candesartan Cilexetil with Enhanced In Vitro and In Vivo Performance
por: Poudel, Surendra, et al.
Publicado: (2021)

Efficacy of azilsartan on left ventricular diastolic dysfunction compared with candesartan: J-TASTE randomized controlled trial
por: Ito, Shin, et al.
Publicado: (2023)

A validated ultra high-pressure liquid chromatography method for separation of candesartan cilexetil impurities and its degradents in drug product
por: Kumar, Namala Durga Atchuta, et al.
Publicado: (2012)

Enhancing the Oral Bioavailability of Candesartan Cilexetil Loaded Nanostructured Lipid Carriers: In Vitro Characterization and Absorption in Rats after Oral Administration
por: Anwar, Walid, et al.
Publicado: (2020)

Candesartan cilexetil prevents diet-induced insulin resistance via peroxisome proliferator-activated receptor-γ activation in an obese rat model
por: YAN, WEN-HUA, et al.
Publicado: (2016)

Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction
por: Chang, Gwo‐Jyh, et al.
Publicado: (2022)

Pharmacokinetics and bioequivalence of fixed-dose combination of candesartan cilexetil/amlodipine besylate (16/10 mg) versus coadministration of individual formulations in healthy subjects
por: Lee, Hae Won, et al.
Publicado: (2020)

Pharmacokinetics of a Single Dose of Azilsartan in Pediatric Patients: A Phase 3, Open-Label, Multicenter Study
por: Enya, Kazuaki, et al.
Publicado: (2018)

A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension
por: Wu, Jiahui, et al.
Publicado: (2020)

A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension: Erratum
Publicado: (2020)

Azilsartan Improves Salt Sensitivity by Modulating the Proximal Tubular Na(+)-H(+) Exchanger-3 in Mice
por: Hatanaka, Masaki, et al.
Publicado: (2016)

Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study
por: Ito, Sadayoshi, et al.
Publicado: (2019)

Candesartan Cilexetil Improves Angiotensin II Type 2 Receptor–Mediated Neurite Outgrowth via the PI3K-Akt Pathway in Fructose-Induced Insulin-Resistant Rats
por: Hashikawa-Hobara, Narumi, et al.
Publicado: (2012)

Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension
por: Juhasz, Attila, et al.
Publicado: (2018)

Twenty‐Four‐Hour Blood Pressure‐Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double‐Blind Multicenter Study
por: Kario, Kazuomi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1sdlof38vnru3kl1s9kferd0uc